Jazz Pharmaceuticals to Participate in TD Cowen's 45th Annual Health Care Conference

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) has announced its participation in TD Cowen's 45th Annual Health Care Conference. The company's management will engage in a fireside chat scheduled for March 5, 2025, at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.

The event will be accessible via audio webcast through the Investors section of Jazz Pharmaceuticals' website, with recordings available for 30 days post-event. Jazz Pharmaceuticals is a global biopharma company focused on developing life-changing medicines for patients with serious diseases, particularly in areas with therapeutic options.

The company maintains a diverse portfolio of marketed medicines, specializing in sleep disorders and epilepsy treatments, along with an expanding cancer treatment portfolio. Their research and development efforts span both oncology and neuroscience, with operations and facilities across multiple countries, headquartered in Dublin, Ireland.

DUBLIN, Feb. 20, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in TD Cowen's 45^th Annual Health Care Conference. Company management will participate in a fireside chat on Wednesday, March 5, 2025, at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.

An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-td-cowens-45th-annual-health-care-conference-302381787.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When is Jazz Pharmaceuticals (JAZZ) presenting at TD Cowen's Healthcare Conference 2025?

Jazz Pharmaceuticals will participate in a fireside chat on Wednesday, March 5, 2025, at 7:30 a.m. PT / 10:30 a.m. ET / 3:30 p.m. GMT.

How long will the JAZZ conference webcast be available for replay?

The webcast replay will be archived on Jazz Pharmaceuticals' investor website for 30 days following the event.

What are the main therapeutic areas for Jazz Pharmaceuticals (JAZZ)?

Jazz Pharmaceuticals focuses on sleep disorders, epilepsy treatments, and has a growing portfolio of cancer treatments, with ongoing research in oncology and neuroscience.

Where can investors access the JAZZ TD Cowen conference webcast?

Investors can access the audio webcast through the Investors section of Jazz Pharmaceuticals' website at https://investor.jazzpharma.com/investors/events-presentations.

What is Jazz Pharmaceuticals' (JAZZ) geographical presence?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with research and development laboratories, manufacturing facilities, and employees across multiple countries globally.